High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli

Biochemical Pharmacology

Volumn 55, Issue 8, 1998, Pages 1315-1325

  Iwata, Hiroshi ^a   Fujita, Ken Ichi ^a   Kushida, Hirotaka ^a   Suzuki, Akihiro ^a   Konno, Yuko ^a   Nakamura, Katsunori ^a   Fujino, Akiharu ^b   Kamataki, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b MITSUBISHI CHEMICAL CORPORATION   (Japan)

Author keywords

Drug metabolism; E. coli; Heterologous expression; Human P450

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 REDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE;

ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME MECHANISM; ENZYME POLYMORPHISM; ENZYME PURIFICATION; ESCHERICHIA COLI; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; CATALYSIS; CLONING, MOLECULAR; CYTOCHROME P-450 ENZYME SYSTEM; ESCHERICHIA COLI; HUMANS; MOLECULAR SEQUENCE DATA; NADH, NADPH OXIDOREDUCTASES; NADPH-FERRIHEMOPROTEIN REDUCTASE; RECOMBINANT PROTEINS;

EID: 0032522904     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00643-6     Document Type: Article

References (73)

1. Porter TD, Coon MJ. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J Biol Chem. 266:1991;13469-13472.
2. Guengerich FP. Reactions and significance of cytochrome P450 enzymes. J Biol Chem. 266:1991;10019-10022.
3. Guengerich FP. Cytochrome-P450 enzymes. Am Sci. 81:1993;440-447.
4. Thakker DR, Yagi H, Levin W, Conney AH, Jerina DM. Polycyclic aromatic hydrocarbons Metabolic activation to ultimate carcinogens . Andes MW. Bioactivation of Foreign Compounds. 1985;178-242 Academic Press, New York.
5. Gillam EMJ, Baba T, Kim BR, Ohmori S, Guengerich FP. Expression of modified human cytochrome P4503A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys. 305:1993;123-131.
6. Barnes HJ, Arlotto MF, Waterman MR. Expression and enzymatic activity of recombinant cytochrome P450 17α-hydroxylase in Escherichia coli. Proc Natl Acad Sci USA. 88:1991;5597-5601.
7. Richardson TH, Hsu MH, Kronbach T, Barnes HJ, Chan G, Waterman MR, Kemper B, Johnson EF. Purification and characterization of recombinant-expressed cytochrome P450 2C3 from Escherichia coli 2C3 encodes the 6β-hydroxylase deficient form of P450 3b . Arch Biochem Biophys. 300:1993;510-516.
8. Fisher CW, Caudle DL, Martin-Wixtrom C, Quattrochi LC, Tukey RH, Waterman MR, Estabrook RW. High-level expression of functional human cytochrome P450 1A2 in Escherichia coli. FASEB J. 6:1992;759-764.
9. 2-terminal segment retains catalytic activity and is membrane-bound when expressed in Escherichia coli. J Biol Chem. 266:1991;7321-7324.
10. Shimada T, Gillam EMJ, Sandhu P, Guo ZY, Tukey RH, Guengerich FP. Activation of procarcinogens by human cytochrome P450 enzymes expressed in Escherichia coli. Simplified bacterial system for genotoxicity assays. Carcinogenesis. 15:1994;2523-2529.
11. Bligh HFJ, Wolf CR, Smith G, Beggs JD. Production of cytochrome P450 reductase yeast-rat hybrid proteins in Saccharomyces cerevisiae. Gene. 110:1992;33-39.
12. Renaud JP, Peyronneau MA, Urban P, Truan G, Cullin C, Pompon D, Beaune P, Mansuy D. Recombinant yeast in drug metabolism. Toxicology. 82:1993;39-52.
13. 1. Proc Natl Acad Sci USA. 85:1988;5769-5773.
14. 1. Proc Natl Acad Sci USA. 87:1990;4790-4793.
15. 1 and comparison to CYP1A2 and CYP2A3 . Drug Metab Dispos. 22:1991;688-692.
16. Schneider A, Schmalix WA, Siruguri V, Groene EM, Harbach GJ, Kleingeist B, Lang D, Böcker R, Belloc C, Beaune P, Greim H, Doehmer J. Stable expression of human cytochrome P450 3A4 in conjunction with human NADPH-cytochrome P450 oxidoreductase in V79 Chinese hamster cells. Arch Biochem Biophys. 332:1996;295-304.
17. Gonzalez FJ, Korzekwa KR. Cytochrome P450 expression systems. Annu Rev Pharmacol Toxicol. 35:1995;369-390.
18. Sandhu P, Baba T, Guengerich FP. Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Arch Biochem Biophys. 306:1993;443-450.
19. Guo Z, Gillam EMJ, Ohmori S, Tukey RH, Guengerich FP. Expression of modified human P450 1A1 in Escherichia coli Effects of 5′ substitution, stabilization, purification, spectral characterization, and catalytic properties . Arch Biochem Biophys. 312:1994;436-446.
20. Sandhu P, Guo Z, Baba T, Martin MV, Tukey RH, Guengerich FP. Expression of modified human cytochrome P450 1A2 in Escherichia coli Stabilization, purification, spectral characterization, and catalytic activities of the enzyme . Arch Biochem Biophys. 309:1994;168-177.
21. Gillam EMJ, Guo Z, Guengerich FP. Expression of modified human cytochrome P450 2E1 in Escherichia coli, purification, and spectral and catalytic properties. Arch Biochem Biophys. 312:1994;59-66.
22. Gillam EMJ, Guo Z, Ueng YF, Yamazaki H, Cock I, Reilly PEB, Hooper WD, Guengerich FP. Expression of cytochrome P4503A5 in Escherichia coli Effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities . Arch Biochem Biophys. 317:1995;374-384.
23. Gillam EMJ, Guo Z, Martin MV, Jenkins CM, Guengerich FP. Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization. Arch Biochem Biophys. 319:1995;540-550.
24. Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Omiecinski CJ, Johnson EF. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch Biochem Biophys. 323:1995;87-96.
25. Jenkins CM, Waterman MR. Flavodoxin and NADPH-flavodoxin reductase from Escherichia coli support bovine cytochrome P450c17 hydroxylase activities. J Biol Chem. 269:1994;27401-27408.
26. Komori M, Nishio K, Fujitani T, Ohi H, Kitada M, Mima S, Itahashi K, Kamataki T. Isolation of a new human fetal liver cytochrome P450 cDNA clone Evidence for expression of a limited number of forms of cytochrome P450 in human fetal livers . Arch Biochem Biophys. 272:1989;219-225.
27. Ohgiya S, Komori M, Ohi H, Shiramatsu K, Shinriki N, Kamataki T. Six-base deletion occurring in messages of human cytochrome P-450 in the CYP2C subfamily results in reduction of tolbutamide hydroxylase activity. Biochem Int. 27:1992;1073-1081.
28. Komori M, Nishio K, Kitada M, Shiramatsu K, Nuroya K, Soma M, Nagashima K, Kamataki T. Fetus-specific expression of a form of cytochrome P450 in human liver. Biochemistry. 29:1990;4430-4433.
29. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem. 239:1964;2370-2378.
30. Phillips AH, Langdon RG. Hepatic triphosphopyridine nucleotide-cytochrome c reductase Isolation, characterization and kinetic studies . J Biol Chem. 237:1962;2652-2660.
31. Laemmli UK. Cleavage of structural properties during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
32. Burke MD, Mayer RT. Differential effects of phenobarbitone and 3-methylcholanthrene induction of the hepatic microsomal metabolism and cytochrome P-450-binding of phenoxazone and a homologous series of its n-alkyl ethers (alkoxyresorufins). Chem Biol Interact. 45:1983;243-258.
33. Aitio A. A simple and sensitive assay of 7-ethoxycoumarin deethylation. Anal Biochem. 85:1978;488-491.
34. Pearce R, Greenway D, Parkinson A. Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes Effects on coumarin, dicumarol, and testosterone oxidation . Arch Biochem Biophys. 298:1992;211-225.
35. Imai Y, Itoh A, Sato R. Exidence for biochemically different types of vesicles in the hepatic microsomal fraction. J Biochem (Tokyo). 60:1966;417-428.
36. Yasumori T, Murayama N, Yamazoe Y, Abe A, Nogi Y, Fukasawa T, Kato R. Expression of a human P-450IIC gene in yeast cells using galactose-inducible expression system. Mol Pharmacol. 35:1989;443-449.
37. Tassaneeyakul W, Veronese ME, Birkett DJ, Miners JO. High-performance liquid chromatographic assay for 4-nitrophenol hydroxylation, a putative cytochrome P-4502E1 activity, in human liver microsomes. J Chromatogr. 616:1993;73-78.
38. Chen L, Yasumori T, Yamazoe Y, Kato R. Hepatic microsomal tolbutamide hydroxylation in Japanese In vitro evidence for rapid and slow metabolizers . Pharmacogenetics. 3:1993;77-85.
39. Cresteil T, Monsarrat B, Alvinerie P, Tréluyer JM, Vieira I, Wright M. Taxol metabolism by human liver microsomes Identification of cytochrome P450 isozymes involved in its biotransformation . Cancer Res. 54:1994;386-392.
40. Arlotto MP, Trant JM, Estabrook RW. Measurement of steroid hydroxylation reactions by high-performance liquid chromatography as indicator of P450 identity and function. Methods Enzymol. 206:1991;454-462.
41. 1 antagonist promethazine in human liver microsomes. Pharmacogenetics. 6:1996;449-457.
42. Penman BW, Chen L, Gelboin HV, Gonzalez FJ, Crespi CL. Development of a human lymphoblastoid cell line constitutively expressing human CYP1A1 Substrate specificity with model substrates and promutagens . Carcinogenesis. 15:1994;1931-1937.
43. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 29:1990;1322-1329.
44. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54:1994;5543-5546.
45. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry. 33:1994;1743-1752.
46. Küpfer A, Desmond P, Patwardhan R, Schenker S, Branch RA. Mephenytoin hydroxylation deficiency Kinetics after repeated doses . Clin Pharmacol Ther. 35:1984;33-39.
47. Meier UT, Dayer P, Malè P-J, Kronbach T, Meyer UA. Mephenytoin hydroxylation polymorphism Characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivov . Clin Pharmacol Ther. 38:1985;488-494.
48. Dayer P, Leemann T, Küpfer A, Kronbach T, Meyer UA. Stereo- and regioselectivity of hepatic oxidation in man - Effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation. Eur J Clin Pharmacol. 31:1986;313-318.
49. Lasker JM, Raucy J, Kubota S, Bloswick BP, Black M, Lieber CS. Purification and characterization of human liver cytochrome P-450-ALC. Biochem Biophys Res Commun. 148:1987;232-238.
50. Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzalez FJ, Miners JO. Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem Pharmacol. 46:1993;1975-1981.
51. Kawano S, Kamataki T, Yasumori T, Yamazoe Y, Kato R. Purification of human liver cytochrome P-450 catalyzing testosterone 6β-hydroxylation. J Biochem (Tokyo). 102:1987;493-501.
52. Bourrié M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther. 277:1996;321-332.
53. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M. Specificity of substrate and inhibitor probes for cytochrome P450s Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes . Xenobiotica. 26:1996;681-693.
54. Williams FM, Mutch E, Woodhouse KW, Lambert D, Rawlins MD. Ethoxyresorufin O-deethylation by human liver microsomes. Br J Clin Pharmacol. 22:1986;263-268.
55. Amri HS, Batt AM, Siest G. Comparison of cytochrome P450 content and activities in liver microsomes of seven animal species, including man. Xenobiotica. 16:1986;351-358.
56. Yun CH, Shimada T, Guengerich FP. Purification and characterization of a human liver microsomal cytochrome P450 2A6. Mol Pharmacol. 40:1991;679-685.
57. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes. Biochem Pharmacol. 37:1988;1137-1144.
58. Meier UT, Kronbach T, Meyer UA. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal Biochem. 151:1985;286-291.
59. Gut J, Meier UT, Catin T, Meyer UA. Mephenytoin-type polymorphism of drug oxidation Purification and characterization of a human liver cytochrome P450 ioszyme catalyzing microsomal mephenytoin hydroxylation . Biochim Biophys Acta. 884:1986;435-447.
60. Yamazaki H, Guo Z, Persmark M, Mimura M, Inoue K, Guengerich FP, Shimada T. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol Pharmacol. 46:1994;568-577.
61. Guengerich FP, Distlerath LM, Reilly PEB, Wolff T, Shimada T, Umbenhauer DR, Martin MV. Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation. Xenobiotica. 16:1986;367-378.
62. Gut J, Gasser R, Dayer P, Kronbach T, Catin T, Meyer UA. Debrisoquine-type polymorphism of drug oxidation Purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation . FEBS Lett. 173:1984;287-290.
63. Dong J, Porter TD. Coexpression of mammalian cytochrome P450 and reductase in Escherichia coli. Arch Biochem Biophys. 327:1996;254-259.
64. Porter TD. Mutagenesis at a highly conserved phenylalanine in cytochrome P450 2E1 affects heme incorporation and catalytic activity. Biochemistry. 33:1994;5942-5946.
65. Wrighton SA, Thomas PE, Ryan DE, Levin W. Purification and characterization of ethanol-inducible human hepatic cytochrome P-450HLj. Arch Biochem Biophys. 258:1987;292-297.
66. Blake JAR, Pritchard M, Ding S, Smith GCM, Burchell B, Wolf CR, Friedberg T. Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli. FEBS Lett. 397:1996;210-214.
67. Lee CA, Kadwell SH, Kost TA, Serabjit-Singh CJ. CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. Arch Biochem Biophys. 319:1995;157-167.
68. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism Identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme . Arch Biochem Biophys. 263:1988;424-436.
69. Vermilion JL, Coon MJ. Purified liver microsomal NADPH-cytochrome P-450 reductase. J Biol Chem. 253:1978;2694-2704.
70. Kamataki T, Belcher DH, Neal RA. Studies of the metabolism of diethyl p-nitrophenol phosphothionate (parathion) and benzphetamine using an apparently homogeneous preparation of rat liver cytochrome P-450 Effect of a cytochrome P-450 antibody preparation . Mol Pharmacol. 12:1976;921-932.
71. 5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and human liver microsomes. Biochem Pharmacol. 52:1996;301-309.
72. 5 potentiation of cytochrome P-450 catalytic activity demonstrated by a vaccinia virus-mediated in situ reconstitution system. Proc Natl Acad Sci USA. 87:1990;5425-5429.
73. 5. Eur J Biochem. 207:1992;109-116.